Focal Adhesion Kinase (FAK) Over-Expression and Prognostic Implication in Pediatric Hepatocellular Carcinoma

Focal Adhesion Kinase (FAK) Over-Expression and Prognostic Implication in Pediatric Hepatocellular Carcinoma

Focal adhesion kinase (FAK) is over-expressed and is correlated with aggressiveness in adult hepatocellular carcinoma (HCC). Inhibition of FAK decreases HCC invasiveness by down-regulating Enhancer of Zeste homolog 2 (EZH2), an epigenetic controller, that acts in transcriptional repression of a larg...

Full description

Bibliographic Details
Main Authors:	Paola Francalanci, Isabella Giovannoni, Cristiano De Stefanis, Ilaria Romito, Chiara Grimaldi, Aurora Castellano, Valentina D’Oria, Rita Alaggio, Anna Alisi
Format:	Article
Language:	English
Published:	MDPI AG 2020-08-01
Series:	International Journal of Molecular Sciences
Subjects:	pediatric hepatocellular carcinoma focal adhesion kinase enhancer of Zeste homolog 2 β-Catenin cirrhosis normal liver
Online Access:	https://www.mdpi.com/1422-0067/21/16/5795

Similar Items

Emodin succinyl ester inhibits malignant proliferation and migration of hepatocellular carcinoma by suppressing the interaction of AR and EZH2
by: Hanif Khan, et al.
Published: (2020-08-01)

Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma
by: Nadia Panera, et al.
Published: (2017-01-01)

Silencing Of hsa_circ_0008450 Represses Hepatocellular Carcinoma Progression Through Regulation Of microRNA-214-3p/EZH2 Axis
by: Lin T, et al.
Published: (2019-10-01)

EZH2 Contributes To Cisplatin Resistance In Breast Cancer By Epigenetically Suppressing miR-381 Expression
by: Dou D, et al.
Published: (2019-11-01)

EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment
by: Yatao Yin, et al.
Published: (2017-11-01)

Activation of miR-101-3p/EZH2 pathway enhances sorafenib sensitivity of HepG2 cells
by: ZHANG Yueting, et al.
Published: (2020-11-01)

Current advances of targeting epigenetic modifications in neuroendocrine prostate cancer
by: Wen-Chi Cheng, et al.
Published: (2021-01-01)

Impact of Enhancer of Zeste Homolog 2 on T Helper Cell-Mediated Allergic Rhinitis
by: Tsung-Yun Hou, et al.
Published: (2017-07-01)

EZH2 contributes to 5-FU resistance in gastric cancer by epigenetically suppressing FBXO32 expression
by: Wang C, et al.
Published: (2018-11-01)

The Role of the FAT Domain in Controlling Localization and Activation of the Focal Adhesion Kinase (FAK)
by: Naser, Rayan Mohammad Mahmoud
Published: (2019)

Epigenetic Silencing of miR-9 Promotes Migration and Invasion by EZH2 in Glioblastoma Cells
by: Yi-Chung Chien, et al.
Published: (2020-07-01)

Panobinostat and its combination with 3-deazaneplanocin-A induce apoptosis and inhibit In vitro tumorigenesis and metastasis in GOS-3 glioblastoma cell lines
by: Javier de la Rosa, et al.
Published: (2018-01-01)

Benign hepatocellular nodules of healthy liver: focal nodular hyperplasia and hepatocellular adenoma
by: Massimo Roncalli, et al.
Published: (2016-06-01)

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
by: Carlos J Diaz Osterman, et al.
Published: (2019-09-01)

A rare diagnosis of a focal liver lesion
by: Alberto Del Prato, et al.
Published: (2015-03-01)

MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2
by: De-Ning Ma, et al.
Published: (2016-01-01)

EZH2 upregulation by ERα induces proliferation and migration of papillary thyroid carcinoma
by: Liqiong Xue, et al.
Published: (2019-11-01)

MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2
by: Jing Chen, et al.
Published: (2017-02-01)

STAT3-Induced Upregulation of lncRNA CASC9 Promotes the Progression of Bladder Cancer by Interacting with EZH2 and Affecting the Expression of PTEN
by: Yuan B, et al.
Published: (2020-09-01)

FAK displacement from focal adhesions: a promising strategy to target processes implicated in cancer progression and metastasis
by: Ioanna Antoniades, et al.
Published: (2021-01-01)

Apparent diffusion coefficient for differentiating between benign and malignant hepatic focal lesions
by: Sherif Abugamra, et al.
Published: (2020-12-01)

EZH2 as a Regulator of CD8+ T Cell Fate and Function
by: Christopher J. Stairiker, et al.
Published: (2020-10-01)

Indirect Tumor Inhibitory Effects Of MicroRNA-124 Through Targeting EZH2 In The Multiple Myeloma Cell Line
by: Javid Sabour Takanlu, et al.
Published: (2020-04-01)

Role of EZH2 in the Growth of Prostate Cancer Stem Cells Isolated from LNCaP Cells
by: Kewei Xu, et al.
Published: (2013-06-01)

Polycomb Repressor Complex 2 in Genomic Instability and Cancer
by: Zoe Veneti, et al.
Published: (2017-07-01)

EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice
by: Lingling Wu, et al.
Published: (2021-03-01)

FAK Structure and Regulation by Membrane Interactions and Force in Focal Adhesions
by: Paula Tapial Martínez, et al.
Published: (2020-01-01)

Lacosamide as add-on treatment of focal symptomatic epilepsy in a patient with alcoholic liver cirrhosis
by: A. Romigi, et al.
Published: (2014-01-01)

Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy
by: Xiao-Jing Pang, et al.
Published: (2021-07-01)

Machine Learning-Based Ultrasomics Improves the Diagnostic Performance in Differentiating Focal Nodular Hyperplasia and Atypical Hepatocellular Carcinoma
by: Wei Li, et al.
Published: (2021-03-01)

TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2
by: Caihui Xu, et al.
Published: (2018-11-01)

LINC02678 as a Novel Prognostic Marker Promotes Aggressive Non-small-cell Lung Cancer
by: Dexin Jia, et al.
Published: (2021-05-01)

NEXAVAR IN TREATMENT OF HEPATOCELLULAR CARCINOMA
by: Gabriela Smira, et al.
Published: (2018-12-01)

Combined Chibby and β-Catenin Predicts Clinical Outcomes in Patients with Hepatocellular Carcinoma
by: Ming-Chao Tsai, et al.
Published: (2020-03-01)

Synchronous Hepatocellular Carcinoma and Cholangiocarcinoma in a Patient Transplanted for Cryptogenic Cirrhosis
by: B Geramizadeh, et al.
Published: (2014-07-01)

A CT-based radiomics nomogram for differentiation of focal nodular hyperplasia from hepatocellular carcinoma in the non-cirrhotic liver
by: Pei Nie, et al.
Published: (2020-02-01)

Serum Myostatin Predicts the Risk of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Multicenter Study
by: Ji Hyun Kim, et al.
Published: (2020-11-01)

Hiperplasia nodular focal múltipla do fígado: subtipo misto hiperplásico/adenomatoso
by: Raul Guilherme Azevedo Macedo, et al.

EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
by: Hao Gong, et al.
Published: (2020-12-01)

Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non‐small cell lung cancer
by: Bin Shi, et al.
Published: (2019-10-01)